The use of a vaccine-based approach to prostate cancer suffered yet another blow Jan. 11 when Germany’s CureVac AG reported disappointing results for its RNActive prostate cancer vaccine CV9104 in a Phase IIb clinical trial. However, there may be good reasons not to be too downcast; there are more than half-a-dozen other potential therapeutic vaccines in late-stage clinical studies, according to Informa Pharma Intelligence’s database, Biomedtracker.
Not only that, the world’s first therapeutic prostate cancer vaccine, Dendreon Corp.’s Provenge (sipuleucel-T), which was first approved for...





![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)
